Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Gamma-aminobutyric acid type A (GABAA) receptor α2β2γ3 is a heteropentameric ligand-gated ion channel that serves as a primary mediator of rapid inhibitory synaptic transmission in the mammalian central nervous system (StatPearls, 2023). This specific receptor assembly consists of two α2 subunits, two β2 subunits, and one γ3 subunit, which together form a transmembrane pore selective for chloride ions (UniProt, 2024). Upon binding of the neurotransmitter GABA, the receptor undergoes a conformational change that opens the pore, leading to chloride influx and subsequent hyperpolarization of the postsynaptic membrane, which reduces neuronal excitability (IUPHAR/BPS, 2024). Receptors containing the α2 subunit are highly concentrated in limbic structures such as the amygdala and hippocampus, and they are specifically associated with the mediation of anxiolytic and anticonvulsant effects (PubMed, PMID: 12171570). Pharmacologically, this subtype is a target for various classes of drugs, including benzodiazepines, barbiturates, and neurosteroids, which act as positive allosteric modulators to enhance the inhibitory action of GABA (PubChem, 2024). Development of α2-selective modulators is a key strategy in neuropsychopharmacology to create treatments for anxiety and epilepsy that lack the sedative and amnestic side effects typically mediated by α1-containing GABAA receptors (Nature Reviews Drug Discovery, 2005). Dysregulation or genetic variants of the α2, β2, or γ3 subunits have been linked to conditions such as generalized anxiety disorder, alcohol dependence, and schizophrenia (NCBI Gene, 2024).
Positive allosteric modulation of the GABAA receptor, which increases the frequency of chloride channel opening in response to GABA binding, thereby enhancing inhibitory neurotransmission (StatPearls, 2023; IUPHAR/BPS, 2024).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gamma-aminobutyric acid type A receptor alpha-2 beta-2 gamma-3 (GABAA receptor α2β2γ3) (GABAA receptor α2β2γ3).